ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,200Medicare Part D Prescriptions Filled, Including Refills

Rank: 39 out of 559

$477K Total Retail Price of All Prescriptions

Rank: 37 out of 559

470 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
32% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Mexico
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 470 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

9% of this provider’s 470 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 6,718 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$52 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Mexico
LEVOTHYROXINE SODIUM 820 607 1 2
SIMVASTATIN 552 423 2 3
LISINOPRIL 332 275 3 1
LOSARTAN POTASSIUM 301 276 4 14
OMEPRAZOLE 237 175 5 4
AMLODIPINE BESYLATE 219 193 6 6
HYDROCHLOROTHIAZIDE 171 137 7 8
METFORMIN HCL 156 121 8 5
FLUTICASONE PROPIONATE 147 89 9 22
HYDROCODONE-ACETAMINOPHEN 137 87 S3 10 7
CRESTOR 137 104 10 33
GABAPENTIN 136 108 12 9
ALENDRONATE SODIUM 134 96 13 13
PANTOPRAZOLE SODIUM 132 90 14 41
METOPROLOL SUCCINATE 121 104 15 16
POTASSIUM CHLORIDE 116 103 16 23
LOVASTATIN 110 110 17 10
SERTRALINE HCL 109 90 18 19
ATENOLOL 109 98 18 15
LISINOPRIL-HYDROCHLOROTHIAZIDE 109 93 18 18
FELODIPINE ER 104 104 21 72
LOSARTAN-HYDROCHLOROTHIAZIDE 103 81 22 52
ZOLPIDEM TARTRATE 102 52 23 17
RANITIDINE HCL 95 40 24 26
PAROXETINE HCL 92 78 25 48
CITALOPRAM HBR 91 54 26 21
FLUOXETINE HCL 90 57 27 37
METOPROLOL TARTRATE 87 72 28 12
JANUVIA 86 64 29 50
ADVAIR DISKUS 84 68 30 46
FUROSEMIDE 75 58 31 11
INSULIN SYRINGE 69 60 32 65
TRAZODONE HCL 68 57 33 28
CELEBREX 68 53 33 86
OXYCODONE HCL 67 30 S2 35 32
OXYCONTIN 67 41 S2 35 122
ESTRADIOL 63 38 R 37 117
GLIPIZIDE ER 62 53 38 77
TRAMADOL HCL 62 47 38 27
BACLOFEN 61 41 40 90
DOXAZOSIN MESYLATE 55 28 41 43
IBUPROFEN 54 24 42 30
NAMENDA 50 43 43 56
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 11, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.